StockWireNews
Low Float Nasdaq Profile (BSGM) Reaches 2.5 Month New High On Today's Breaking News
$13.00 Laidlaw & Company Price Target
June 30th
Good Morning,
BSGM continues to heat up this morning.
Reaching a new 2.5 month high of $4.58, BSGM has hit levels it hasn't seen since mid-April.
Could this be a sign of things to come in the near term?
As I mentioned in earlier emails, this profile could be on the verge of a squeeze if potential resistance continues to break down at its 200-Day Simple Moving Average.
Let's take a sec to check out some of today's big news:
BioSig Completes 1000 Patient Cases with its Signal Processing System for Electrophysiology
- The Company recently increased its procedural volume targets due to accelerated technology usage
- BioSig expands its commercial team to target technology adoption across three strategic regions
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that physicians have completed 1000 patient cases with its technology across nine installation sites.
Read the full article here.
Take a moment now and read my initial report below on BSGM before it's too late.
-----
*BioSig Technologies, Inc. (BSGM)*
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.
The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Here’s Why PURE EP Could Be a Game-Changer
According to XTalks, PURE EP could fill a significant need because:
“The electrograms used today can be riddled with noise and artifacts coming from other equipment found in the operating room. Such a procedure can take up to six hours, potentially yielding what is referred to in the industry as a ‘dirty signal’ that’s indiscernible to interpret by many electrophysiologists.” (1)
BioSig's PURE EP was developed to address unmet needs in a large and growing market and deliver technology to improve catheter ablation treatments for arrhythmias, Atrial Fibrillation, and Ventricular Tachycardia.
“The system is intended to acquire, digitize, amplify, filter, measure and calculate, display, record and store electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory under the supervision of licensed healthcare practitioners who are responsible for interpreting the data,” as further reported XTalks. (1)
-----
No. 1 Potential Immediate Term Catalyst - Company's Tech To Be Featured At Stanford Retreat
BioSig’s Signal Processing Technology for Electrophysiology To Be Featured During 2021 Stanford Biodesign New Arrhythmia Technologies Retreat
Westport, CT, June 28, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company would be presenting during 2021 Stanford Biodesign New Arrhythmia Technologies Retreat, due to take place virtually on July 27, 2021. The Company will present at 2 pm PT.
[...]
Read the full article here.
-----
No. 2 Potential Immediate Term Catalyst - Potential Squeeze On Horizon?
Check out BSGM's 6-month chart below: